Zouher Majd

This inventor holds 7 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignee: Genfit. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zouher Majd. Retrieved from https://idiyas.com/inventor/zouher-majd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 7 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 13)

EPO Patents = 6 (Patent Applications = 14)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 13(Granted Patents)

Company Filing History:

7 out of 72

Genfit

patents

Years Active: 2018-2026

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12638460 - METHOD FOR NASH RISK ASSESSMENT (2026-05-26),

2. 11974997 - RORgamma modulators and uses thereof (2024-05-07),

3. 11160801 - RORgamma modulators and uses thereof (2021-11-02),

4. 11077115 - Rorgamma modulators and uses thereof (2021-08-03),

5. 11052092 - N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases (2021-07-06),

6. 10987351 - RORgamma modulators and uses thereof (2021-04-27),

7. 9902725 - Heterocyclic derivatives as RORgamma modulators (2018-02-27),

Title: Zouher Majd: Innovator in RORgamma Modulation

Introduction

Zouher Majd, based in Ennetières-en-Weppes, France, is a prominent inventor with a notable portfolio of six patents. His innovative work primarily focuses on RORgamma modulators, contributing significantly to the field of therapeutic treatments for various diseases.

Latest Patents

Zouher's latest patents revolve around the development of novel compounds that act as modulators of RORgamma. These compounds have been detailed in his patent applications, providing pharmaceutical compositions intended for treating diseases where RORgamma modulation could be beneficial. This includes conditions such as autoimmune diseases, inflammatory diseases, metabolic disorders, and fibrotic diseases, showcasing a strong potential for impactful medical applications.

Career Highlights

Zouher Majd works at Genfit, a company recognized for its focus on innovative medical solutions. His dedication to research and development in the field of pharmaceutical sciences positions him as a key figure in the advancement of treatments targeting critical health issues.

Collaborations

Throughout his career, Zouher has collaborated with distinguished colleagues, including Jean-Francois Delhomel and Robert Walczak. These partnerships highlight the collaborative spirit within the research community, fostering the development of cutting-edge medical innovations.

Conclusion

Zouher Majd's contributions to the field of patentable inventions, particularly in RORgamma modulation, demonstrate his commitment to advancing healthcare solutions. His innovative compounds hold promise for transforming treatment approaches for a variety of diseases, underscoring the importance of continued research and development in this vital area.

Profile summary based on public USPTO records.